文献速递妇科

美国卵巢癌腹腔热灌注化疗(HIPEC)的应用现状

Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
PubMed 文献 · Gynecol Oncol · 2020-09-22

该研究基于美国550家医院的行政索赔数据库,比较2018年1月van Driel等III期研究发表前后卵巢癌治疗中HIPEC的使用频率及围手术期结局。结果显示,试验发表后97%的HIPEC病例出现,但绝对数量仍有限;HIPEC与更长的住院时间、更高的ICU入住率、并发症率及费用相关,未发现住院死亡或30天再入院。

要点

  • III期研究发表后,97%的HIPEC病例发生,但绝对数量仍有限。
  • HIPEC患者中位住院时间8.4天 vs 非HIPEC 5.7天,ICU入住率63.1% vs 11.0%。
  • HIPEC患者并发症风险约为非HIPEC的1.87倍,直接费用和费用指数更高。

核心结论

  • III期临床试验在高影响力期刊发表后,美国卵巢癌HIPEC的使用增加,但绝对病例数仍有限。
  • HIPEC的纳入与费用增加、住院时间延长、ICU入住率及医院获得性并发症率升高相关。
  • 需要进一步研究评估长期结局,包括发病率和生存率。

研究设计与样本

  • 查询Vizient行政索赔数据库,覆盖美国550家医院,纳入2016年1月至2020年1月的卵巢癌手术,使用ICD-10诊断和操作代码。
  • 通过硫代硫酸钠给药识别HIPEC病例,依据已发表方案。
  • 采用Student t检验和相对风险(RR)分别比较连续变量和列联表。

主要发现

  • 152例卵巢癌患者在39家医院接受HIPEC,20,014例卵巢癌患者在256家医院接受无HIPEC手术。
  • 试验发表后,97%的HIPEC病例发生。
  • HIPEC患者中位住院时间8.4天 vs 非HIPEC 5.7天(p < 0.001)。
  • HIPEC患者ICU入住率63.1% vs 非HIPEC 11.0%(p < 0.001),并发症率RR=1.87(p=0.002)。
  • HIPEC患者直接费用21,825美元 vs 12,038美元(p < 0.001),直接费用指数1.87 vs 1.11(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐,作者指出需要进一步研究评估长期结局,包括发病率和生存率。

局限性

  • 需要进一步研究评估长期结局,包括发病率和生存率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: 1.) To compare frequency of HIPEC use in ovarian cancer treatment before and after publication of the phase III study by van Driel et al. in January 2018. 2.) To compare associated rates of hospital-based outcomes, including length of stay, intensive care unit (ICU) admission, complications, and costs in ovarian cancer surgery with or without HIPEC. METHODS: We queried Vizient's administrative claims database of 550 US hospitals for ovarian cancer surgeries from January 2016-January 2020 using ICD-10 diagnosis and procedure codes. Sodium thiosulfate administration was used to identify HIPEC cases according to the published protocol. Student t-tests and relative risk (RR) were used to compare continuous variables and contingency tables, respectively. RESULTS: 152 ovarian cancer patients had HIPEC at 39 hospitals, and 20,014 ovarian cancer patients had surgery without HIPEC at 256 hospitals. Following the trial publication, 97% of HIPEC cases occurred. During the index admission, HIPEC patients had longer median length of stay (8.4 vs. 5.7 days, p < 0.001) and higher percentage of ICU admissions (63.1% vs. 11.0%, p < 0.001) and complication rates (RR = 1.87, p = 0.002). Index admission direct costs ($21,825 vs. $12,038, p < 0.001) and direct cost index (observed/expected costs) (1.87 vs. 1.11, p < 0.001) were also greater in the HIPEC patients. No inpatient deaths or 30-day readmissions were identified after HIPEC. CONCLUSIONS: Use of HIPEC for ovarian cancer increased in the US after publication of a phase III clinical trial in a high-impact journal, though the absolute number of cases remains modest. Incorporation of HIPEC was associated with increased cost, hospital length of stay, ICU admission, and hospital-acquired complication rates. Further studies are needed in order to evaluate long-term outcomes, including morbidity and survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Charo LM, Jou J, Binder P, et al. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. Gynecol Oncol. 2020. PMID: 32977989. doi:10.1016/j.ygyno.2020.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。